№ lp_1_2_23043
File format: docx
Character count: 41939
File size: 265 KB
Reference no:
COVID-19 mRNA vaccine (5 years and over) PGD
Version no:
v3.0
Valid from:
1 October 2025
Expiry date:
31 January 2026
Developed by:
UKHSA
Healthcare practitioners:
Registered healthcare practitioners identified in section 3
Amendment history:
Updated in versions v1.0, v2.0, and v3.0
Target group:
Eligible individuals aged 5 years and over
Immunisation programme:
National COVID-19 vaccination programme
Eligibility criteria:
Based on age and health conditions
Training requirements:
Compliance with national vaccination training standards
Review panel:
UKHSA Immunisations PGD Expert Panel
Expert authors:
Pharmacist Christina Wilson, Dr Alex Allen, Nurse David Green
NHS England responsibility:
Governance and authorisation
Period of retention:
25 years for NHS England, 8–25 years for providers
NHS England governance:
NHS England accepts responsibility for PGD governance
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
Not specified
Topic:
BDNF expression analysis
Document Type:
Research data
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers in molecular biology and neuroscience
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / city:
United Kingdom
Subject:
COVID-19 vaccination
Document type:
Protocol
Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare providers involved in COVID-19 vaccination
Period of validity:
1 October 2025 – 31 January 2026
Approval date:
12 September 2025
Note:
Revision history
Year:
Not specified
Species:
Piglet
Tissue:
Hippocampus
Gene:
BDNF
Reference gene:
RO
Method:
RT-qPCR
Data type:
Raw quantitative PCR data
Experimental groups:
Control, 18 µg/kg, 46 µg/kg
Measurements:
CT, ΔCT, ΔΔCT, 2^-ΔΔCT, 2^-ΔCT
Statistical parameters:
Average, STDEV
Sample identifiers:
Sample 1–Sample 50
Document type:
Supplementary data table
Year:
2025
Region / City:
Northern Ireland
Topic:
COVID-19 vaccination, mRNA vaccines
Document Type:
Protocol
Organization / Institution:
Strategic Planning and Performance Group (SPPG), Public Health Agency (PHA)
Author:
Dr. Louise Herron, Mrs. Deirdre Ward, Mrs. Kathryn Turner
Target Audience:
Healthcare professionals administering COVID-19 mRNA vaccines
Period of Validity:
3 April 2025 to 30 June 2025
Approval Date:
3 April 2025
Note:
Change History
Version 1.0:
New national protocol for COVID-19 vaccines (adults) - 5 April 2024
Version 2.0:
Updated to reflect change in vaccine antigenic content - 16 September 2024
Version 3.0:
Updated eligibility criteria for Spring 2025 - 6 March 2025
Year:
2025
Region / city:
United Kingdom
Subject:
COVID-19 vaccination
Document type:
Protocol
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in COVID-19 vaccination
Effective period:
From 1 October 2025 to 31 January 2026
Approval date:
12 September 2025
Note:
Amendment history
v1.0:
6 September 2024
v2.0:
18 February 2025
v3.0:
29 August 2025
Description:
Protocol for the administration of COVID-19 mRNA vaccine to individuals aged 5 years and over, detailing eligibility, vaccine preparation, and staff requirements.
Note:
Year
Authors:
Cassandra M. Juran; Justina Zvirblyte; Yasaman Sharazi; Angela Kubik; Margareth Cheng-Campbell; Elizabeth Blaber; Eduardo Almeida
Affiliations:
Blue Marble Space Institute of Science at NASA Ames Research Center, Mountain View, CA, USA; Vilnius University, Vilnius, Lithuania; Rensselaer Polytechnic Institute, Troy, NY, USA; NASA Ames Research Center, Moffett Field, CA, USA
Research Field:
Stem cell biology; Bone regeneration; Mechanobiology; Space biology
Key Gene:
CDKN1A (Cdkn1a)
Experimental Models:
Wildtype and Cdkn1a-null mice
Methods:
Single-cell mRNA sequencing; in-vitro mechanical stretch; hindlimb unloading; running wheel and treadmill loading; spaceflight microgravity exposure
Space Mission:
Rodent Research-10 aboard the International Space Station
Duration of Spaceflight:
30 days
Biological Material:
Femur bone marrow; mesenchymal osteoprogenitors; osteoblast lineage cells
Type of Document:
Scientific research article
Institutional Context:
NASA-affiliated and academic biomedical research collaboration
Year:
2023
Region / City:
Not specified
Topic:
m6A methylation, NLRP3 mRNA
Document Type:
Research Supplementary Table
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers in molecular biology and genetics
Period of Action:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
International
Subject:
mRNA synthesis and customization
Document Type:
Quotation Request Form
Organization:
Blue Heron Biotech
Target Audience:
Researchers and biotech companies
Required Materials:
DNA template ≥ 20 µg
Template Options:
Circular plasmid or PCR product
Promoter Options:
T7 promoter included or to be added
UTR Options:
5’ and 3’ UTR sequences provided or selected
Modifications:
Pseudouridine, N1-me-pseudouridine, 5-methoxyuridine, 5-me-Cytidine
Purification Methods:
Silica membrane-based or alternative
mRNA Scale Options:
100 µg, 150 µg, 200 µg
QC Tests:
Visual appearance, nanodrop concentration, PAGE/agarose integrity, pH, optional capping efficiency, CE-based size and integrity, endotoxin test
Storage Buffer Options:
Nuclease-free water, 1mM Sodium citrate pH 6.4
Authors:
Tony Malmqvist; Karen Anthony; Jean-Marc Gallo
Affiliation:
Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry, London, United Kingdom
Corresponding Author:
Jean-Marc Gallo
Institutional Address:
King’s College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom
Type of Document:
Scientific research article
Field of Study:
Neuroscience; Molecular and Cellular Biology
Research Subject:
Localization and translation of tau mRNA in rat cortical neurons
Biological Material:
Primary rat cortical neurons
Key Methods:
Fluorescence in situ hybridization (FISH); RNA staining; immunocytochemistry
Key Molecules:
Tau mRNA; eukaryotic elongation factor 1A (eEF1A); neurofilament heavy subunit (NF-H)
Geographical Context:
London, United Kingdom
Institutional Context:
King’s College London, Institute of Psychiatry
Language:
English
Year:
2026
Region / Institution:
Not specified
Topic:
Immunology, SARS-CoV-2, Vaccine Response
Document type:
Peer Review
Author:
Stefania P Bjarnarson
Target audience:
Researchers, Immunologists
Study period:
Up to 33 months post mRNA vaccination
Methods:
Analysis of bone marrow plasma cells, healthy adult donors, post-vaccination sampling
Key findings:
Limited presence of SARS-CoV-2-specific long-lived plasma cells in bone marrow after mRNA vaccination or hybrid immunity
Data source:
Bone marrow aspirates, hip joint replacement surgery samples
Limitations:
Small sample size, discrepancies in patient description, consideration of asymptomatic infections
Scientific relevance:
Provides evidence on the longevity of humoral immune response post-vaccination
Concise description:
Peer-reviewed evaluation of a study assessing the presence of SARS-CoV-2-specific long-lived plasma cells in the bone marrow following mRNA vaccination and hybrid immunity, highlighting methodology, key results, and points for revision.
Year:
2016
Region / city:
Not specified
Topic:
Methods
Document type:
Research Methodology
Organization:
Not specified
Author:
Not specified
Target audience:
Researchers in the field of molecular biology
Period of validity:
Not specified
Date of approval:
Not specified
Date of modification:
Not specified
Year:
2021
Region / city:
Australia
Theme:
Medical Research, mRNA Clinical Trials
Document Type:
Grant Application Guidelines
Organization / Institution:
Department of Industry, Science, Energy and Resources
Author:
Department of Industry, Science, Energy and Resources
Target Audience:
Researchers, Institutions, Organizations applying for MRFF grants
Period of Validity:
2021-2022
Approval Date:
December 2021
Amendment Date:
None
Program:
MRFF – 2021 mRNA Clinical Trial Enabling Infrastructure
Eligibility Criteria:
State government partner required, Organization must be incorporated in Australia, Entity type selection
Required Documents:
Financial details, ABN, Program selection
Supported Browsers:
Mozilla Firefox, Google Chrome, Microsoft Edge (Windows), Safari, Google Chrome (Mac)
Description:
Online application form for the MRFF 2021 mRNA Clinical Trial Enabling Infrastructure grant opportunity outlining instructions and eligibility criteria for applicants.
Year:
2016–2021
Field:
Cancer Genomics
Research Topic:
Lung Adenocarcinoma (LUAD) Molecular Subtypes
Document Type:
Supplementary Scientific Notes and Figures
Study Context:
Comparative analysis with Chen et al. 2016 study and related genomic datasets
Data Sources:
TCGA LUAD cohort; CCLE LUAD cell lines; CPTAC LUAD cohort
Analytical Methods:
mRNA expression clustering; GSVA pathway analysis; MutSig2CV mutation analysis; GISTIC2.0 copy number analysis; Cox proportional hazards modeling
Key Molecular Features:
STK11/KRAS co-mutation; MET activation; stem cell gene signature
Subtype Classification:
Five LUAD mRNA expression subtypes (S1–S5)
Comparative Subtypes Referenced:
PP, PI, TRU expression-based subtypes
Genomic Data Types:
DNA copy number; DNA methylation; mRNA expression; miRNA expression; protein expression
Immune Phenotyping Source:
TCGA H&E image–based immune scores
Gene Signature Components:
C6orf62; DNER; NELL2; LATS2; LGR5; PTPRO; LRIG1; PABPC1; NT5E; SET
Referenced Studies:
Chen et al., 2016; Huang et al., 2021; Thorsson et al., 2018
Year:
2018
Region / City:
Queensland
Topic:
Legal Procedure
Document Type:
Court Order
Organization / Institution:
Supreme Court of Queensland
Author:
N/A
Target Audience:
Legal professionals
Effective Period:
Until further order of the Court
Approval Date:
2018
Amendment Date:
N/A
Context:
A document outlining the terms and procedures for document management and disclosure in legal proceedings, as agreed by the parties in a case before the Supreme Court of Queensland.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / City:
[insert local health board name]
Topic:
Community Pharmacy, Common Ailments Service, Docusate Sodium
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
Welsh Medicines Advice Service
Author:
Dianne Burnett
Target Audience:
Pharmacists working within the Common Ailments Service of the Clinical Community Pharmacy Service
Period of Validity:
01 November 2025 - 31 October 2028
Approval Date:
29 August 2025
Review Date:
31 July 2028
Expiration Date:
31 October 2028
Year:
2025
Region / city:
[insert local health board name]
Theme:
Vaccination
Document type:
Patient Group Direction (PGD)
Authorising organisation:
NHS Wales
Target audience:
Healthcare professionals (Registered)
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
07 August 2025
Amendment date:
30 June 2025
Review date:
01 July 2026
Expiry date:
31 March 2026
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025